Dietary magnesium intake and risk of stroke: a meta-analysis of prospective studies

Division of Nutritional Epidemiology, National Institute of Environmental Medicine, Stockholm, Sweden.
American Journal of Clinical Nutrition (Impact Factor: 6.92). 12/2011; 95(2):362-6. DOI: 10.3945/ajcn.111.022376
Source: PubMed

ABSTRACT Prospective studies of dietary magnesium intake in relation to risk of stroke have yielded inconsistent results.
We conducted a dose-response meta-analysis to summarize the evidence regarding the association between magnesium intake and stroke risk.
Relevant studies were identified by searching PubMed and EMBASE from January 1966 through September 2011 and reviewing reference lists of retrieved articles. We included prospective studies that reported RRs with 95% CIs of stroke for ≥3 categories of magnesium intake. Results from individual studies were combined by using a random-effects model.
Seven prospective studies, with 6477 cases of stroke and 241,378 participants, were eligible for inclusion in the meta-analysis. We observed a modest but statistically significant inverse association between magnesium intake and risk of stroke. An intake increment of 100 mg Mg/d was associated with an 8% reduction in risk of total stroke (combined RR: 0.92; 95% CI: 0.88, 0.97), without heterogeneity among studies (P = 0.66, I(2) = 0%). Magnesium intake was inversely associated with risk of ischemic stroke (RR: 0.91; 95% CI: 0.87, 0.96) but not intracerebral hemorrhage (RR: 0.96; 95% CI: 0.84, 1.10) or subarachnoid hemorrhage (RR: 1.01; 95% CI: 0.90, 1.14).
Dietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Many studies have focused on the association of tea consumption and the risk and progression of prostate cancer (PCa). However, the evidence is inadequate to draw robust conclusions. To shed light on these inconclusive findings, we conducted a meta-analysis. We searched the database of PubMed and Web of Science for eligible articles. The relevant data were abstracted by two independent reviewers and performed with Stata 11.0. 21 studies were included. The pooled outcomes showed that there was a significant association between tea consumption and PCa risk (OR=0.84, 95% CI (0.71-0.98)); tea consumption could reduce PCa risk in China and India (OR=0.40 and 0.48, 95% CI (0.25-0.66) and (0.24-0.97), respectively); both green and black tea consumption showed no significant effect on PCa risk (OR=0.73 and 0.95, 95% CI (0.52-1.02) and (0.82-1.11), respectively); the highest level tea consumption showed significant protective effect on the low-grade PCa (OR=0.66, 95% CI (0.46-0.93)); no significant effect was found in both localized and advanced PCa in stage subgroup analyses (OR=1.12 and 0.85, 95% CI (0.82-1.54) and (0.62-1.16), respectively). The results show that regardless of tea type, tea consumption might be a potential protective factor for the PCa, especially in China and India. Tea consumption might be the protective factor for low-grade PCa. However, more relevant studies are needed to further explore this association.
    International Journal of Clinical and Experimental Medicine 01/2014; 7(11):3881-91. · 1.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An effect of multivitamin supplement on stroke risk is uncertain. We aimed to examine the association between multivitamin use and risk of death from stroke and its subtypes. A total of 72 180 Japanese men and women free from cardiovascular diseases and cancers at baseline in 1988 to 1990 were followed up until December 31, 2009. Lifestyles including multivitamin use were collected using self-administered questionnaires. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) of total stroke and its subtypes in relation to multivitamin use. During a median follow-up of 19.1 years, we identified 2087 deaths from stroke, including 1148 ischemic strokes and 877 hemorrhagic strokes. After adjustment for potential confounders, multivitamin use was associated with lower but borderline significant risk of death from total stroke (HR, 0.87; 95% confidence interval, 0.76-1.01), primarily ischemic stroke (HR, 0.80; 95% confidence interval, 0.63-1.01), but not hemorrhagic stroke (HR, 0.96; 95% confidence interval, 0.78-1.18). In a subgroup analysis, there was a significant association between multivitamin use and lower risk of mortality from total stroke among people with fruit and vegetable intake <3 times/d (HR, 0.80; 95% confidence interval, 0.65-0.98). That association seemed to be more evident among regular users than casual users. Similar results were found for ischemic stroke. Multivitamin use, particularly frequent use, was associated with reduced risk of total and ischemic stroke mortality among Japanese people with lower intake of fruits and vegetables. © 2015 American Heart Association, Inc.
    Stroke 03/2015; DOI:10.1161/STROKEAHA.114.008270 · 6.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multivitamin-mineral (MVM) products are the most commonly used supplements in the United States, followed by multivitamin (MV) products. Two randomized clinical trials (RCTs) did not show an effect of MVMs or MVs on cardiovascular disease (CVD) mortality; however, no clinical trial data are available for women with MVM supplement use and CVD mortality. The objective of this research was to examine the association between MVM and MV use and CVD-specific mortality among US adults without CVD. A nationally representative sample of adults from the restricted data NHANES III (1988-1994; n = 8678; age ≥40 y) were matched with mortality data reported by the National Death Index through 2011 to examine associations between MVM and MV use and CVD mortality by using Cox proportional hazards models, adjusting for multiple potential confounders. We observed no significant association between CVD mortality and users of MVMs or MVs compared with nonusers; however, when users were classified by the reported length of time products were used, a significant association was found with MVM use of >3 y compared with nonusers (HR: 0.65; 95% CI: 0.49, 0.85). This finding was largely driven by the significant association among women (HR: 0.56; 95% CI: 0.37, 0.85) but not men (HR: 0.79; 95% CI: 0.44, 1.42). No significant association was observed for MV products and CVD mortality in fully adjusted models. In this nationally representative data set with detailed information on supplement use and CVD mortality data ∼20 y later, we found an association between MVM use of >3 y and reduced CVD mortality risk for women when models controlled for age, race, education, body mass index, alcohol, aspirin use, serum lipids, blood pressure, and blood glucose/glycated hemoglobin. Our results are consistent with the 1 available RCT in men, indicating no relation with MVM use and CVD mortality. © 2015 American Society for Nutrition.
    Journal of Nutrition 03/2015; 145(3). DOI:10.3945/jn.114.204743 · 4.23 Impact Factor